Results 231 to 240 of about 1,016,262 (299)
A bioengineered mitochondrial respiration‐mimetic nanoplatform (TC@OMG) renews tumor mitochondrial metabolism to enhance cuproptosis. TC@OMG integrates a copper‐based metal‐organic framework co‐loaded with glucose oxidase and a lactate dehydrogenase inhibitor, and is cloaked with a hybrid membrane derived from tumor cells and plant thylakoids, enabling
Liyang Zhou +7 more
wiley +1 more source
Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review. [PDF]
Yang XX +5 more
europepmc +1 more source
Chronic oral administration of specific probiotic strains triggers gut microbiota dysbiosis and systemic metabolic perturbations in mice. Multi‐omics profiling reveals subsequent hippocampal glial remodeling and neuroinflammation, which are linked to cognitive impairment.
Yibin Lin +15 more
wiley +1 more source
The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells. [PDF]
Ochoa TA +4 more
europepmc +1 more source
A transcriptionally distinct intermediate Langerhans cell state is identified between steady and migratory populations during skin injury. Integrated single‐cell transcriptomics, flow cytometry, and intravital imaging reveal state‐specific markers and implicate complement signaling, particularly C3, in regulating Langerhans cell accumulation near ...
Artem Kiselev +5 more
wiley +1 more source
Proteasome Inhibitor MG-132 and PKC-ι-Specific Inhibitor ICA-1S Degrade Mutant p53 and Induce Apoptosis in Ovarian Cancer Cell Lines. [PDF]
Marzan M +7 more
europepmc +1 more source
Pharmacokinetic tuning acts as a programmable mechanistic switch for β‐lap. Sustained low‐concentration exposure redirects β‐lap from NQO1 bioactivation to direct oxidation of vimentin, driving disulfide crosslinking, proteasomal overload and ferroptosis.
Lei Dou +5 more
wiley +1 more source
Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment. [PDF]
Jeon MJ +9 more
europepmc +1 more source
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac +16 more
wiley +1 more source
[Research progress on targeted delivery of proteasome inhibitor nanoparticles for the treatment of multiple myeloma]. [PDF]
Lin YX, Jing DH, Mi JQ.
europepmc +1 more source

